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Abstract
The immune response to antigens is directed in part by the presence or absence of costimulatory
signals. The ability to coincidently present both antigen and, for example, a peptide that inhibits or
activates the costimulatory pathway, would be a valuable tool for tolerization or immunization,
respectively. A simple reaction scheme utilizing oxime chemistry was identified as a means to
efficiently conjugate different peptide species to hyaluronan. Peptides synthesized with an
aminooxy N-terminus reacted directly to hyaluronan under slightly acidic aqueous conditions
without the need for a catalyst. The resulting oxime bond was found to rapidly hydrolyze at pH 2
releasing peptide, but was stable at higher pH values (5.5 and 7). Two different peptide species, a
multiple sclerosis antigen (PLP) and an ICAM-1 ligand (LABL) known to block immune cell
stimulation, were functionalized with the aminooxy end group. These peptides showed similar
reactivity to hyaluronan and were conjugated in an equimolar ratio. The resulting hyaluronan with
grafted PLP and LABL significantly inhibited disease in mice with experimental autoimmune
encephalomyelitis, a model of multiple sclerosis. Aminooxy-peptides facilitate simple synthesis of
multifunctional hyaluronan graft polymers, thus enabling novel approaches to antigen-specific
immune modulation.
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INTRODUCTION
The emergence of nanotechnology has heighted appreciation for the effect of ligand valency
and density, a physical component of molecular signaling. Although carefully synthesized
colloids have become important in this endeavor, researchers have utilized graft polymers to
deliver multivalent signals for decades.[1-5] Antigens grafted to keyhole limpet hemocyanin
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represented an early vaccination scheme that is still employed.[6-9] Today, peptides are
routinely grafted to polymers or to colloids to target drug delivery, mediate endocytosis,
promote tissue growth, modify immune response, and myriad other functions.[10-13]
Grafted peptide number and density have now been recognized as key determinants of
molecular response for many of these systems.[14-17]
Conjugation reactions to orthogonally graft peptides to biological polymers under benign
conditions are, therefore, highly desired tools for mediating multivalent molecular
interactions. In particular, current synthetic approaches for conjugating peptides to
glycosaminoglycans would benefit from simplified reaction schemes.[18] These fragile
biological polymers cannot be exposed to many of the conditions required for traditional
conjugation methods (e.g. solvent, pH, temperature) due to stability concerns.[12] In
addition, current approaches often utilize multiple steps, such as activation procedures to
form reactive intermediates or the addition of linker molecules to facilitate stability or to
improve reaction efficiency.[11, 19, 20] These encumbrances coupled with low product
yields and lengthy purification procedures make many of the current conjugation schemes
inconvenient for translational medicine or assays and impractical for scale-up.[11, 21]
Further problems emerge when conjugating multiple different peptides since small
differences in reactivity may yield unpredictable molar ratios.[22] Such issues hinder the
exploration of multivalent or multifunctional polymers or colloids with defined ligand
densities and ratios.
Oxime chemistry has emerged as a promising conjugation scheme that traditionally utilizes
the highly specific reaction of aminooxy groups to aldehydes or ketones.[23-26] The
reaction can be carried out in water and avoids harsh catalysts or reaction conditions.[27] In
addition, aminooxy reactivity is significantly higher than primary amines, thus conferring
the desired specificity for conjugation schemes using polypeptides.[18, 25, 28] One
drawback to this approach has been the need for available aldehyde or ketone groups to
provide a reactive site, a characteristic that usually necessitates engineering the reactant.
Recent reports, however, have suggested aminooxy compounds reacted directly to
unmodified hyaluronan, thus prompting exploration of oxime chemistry for orthogonal
peptide grafting to this glycosaminoglycan.[23, 29, 30]
Hyaluronan is a flexible, highly water soluble polymer that has been translated into a variety
of medical products, making it an attractive backbone for multivalent peptide grafting.
Additionally, researchers have shown that controlling the size of the hyaluronan scaffold
facilitates placement into lymph nodes after subcutaneous injection. Specifically, hyaluronan
conjugates between 40 – 80 kDa showed a high degree of accumulation in lymph nodes and
minimal systemic exposure [31]. Thus, hyaluronan conjugates in this size range can
passively carry drugs (e.g. immune modulators) to lymph nodes as a means to modify
immune response. In the first part of this paper, oxime chemistry was confirmed as a unique
and simple approach for grafting small molecules or peptides to hyaluronan to create a
lymphatic delivery system.
Furthermore, simultaneous delivery of antigen and an immune modulator represents an
attractive approach to antigen-specific immunotherapy. LABL is a peptide that inhibits the
binding of intracellular cell-adhesion molecule-1 (ICAM-1) [32]. This peptide was also
shown to interfere with immune cell adhesion in immortalized and primary cell culture
models [33-35]. Coincident delivery of antigen and LABL, therefore, may inhibit the
inflammatory immune response and provide ‘antigen-specific’ therapy for treating
autoimmune diseases. Hyaluronan co-grafted with aminooxy-PLP (a multiple sclerosis
antigen) and with aminooxy-LABL was administered subcutaneously in the experimental
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Aminooxy peptides were synthesized using 9-fluorenylmethyloxycarbonyl-protected amino
acid chemistry on polyethylene glycol-polystyrene resins. The peptides synthesized were
aminooxy-LABL (aminooxy-ITDGEATDSG, Ao-LABL), a cell-adhesion molecule
antagonist, and aminooxy-proteolipid peptide (PLP) (aminooxy–HSLGKWLGHPDKF, Ao-
PLP), a known antigen epitope in multiple sclerosis. Peptides were deprotected, cleaved
from resin, and isolated by precipitation in ether. Purification was completed using
preparatory high performance liquid chromatography (HPLC) followed by lyophilization.
Peptide purity was assessed using analytical HPLC and the identity of the synthesized
peptide was confirmed by electrospray ionization mass spectrometry.
Reaction of Aminooxy Molecules to Monomer/Polymer
The reaction conditions were identical for all reactants used (OCMH, OBZ, OPH, LABL
peptide, PLP peptide). Aminooxy monomer was mixed with HA in 1:5 excess in acetate
buffered solution (pH 5.5). After addition of all reactive species, the pH was measured and
adjusted to 5.5 ± 0.1. For reactions, 1.3 μMol HA was dissolved into 20 mM acetate
buffered solution (pH 5.5 ± 0.1). Once dissolved, 1.3 μMol aminooxy-peptide was added to
the solution. When more than one peptide species was added, 0.65 μMol of each peptide
was weighed out separately, then both were added simultaneously. After addition of the
aminooxy species, the reaction solution pH was adjusted to pH 5.5 ± 0.1. The solution was
mixed for 16 hr at room temperature. After 16 hours, the samples were dialyzed against
ddH2O to remove unreacted peptide. Dialysis water was changed every 6 hours for 24
hours. After dialysis, the dialysate was frozen at -70 °C and lyophilized. For kinetic
experiments, samples were taken from the reaction vessel at predetermined time points and
analyzed immediately.
Fourier Transform Infrared Spectroscopy
Changes in bonding environments during reaction were monitored using a Bruker Tensor 27
FTIR spectrometer equipped with a ZnSe attenuated total reflectance (ATR) plate (Pike
Technologies). Fourier transform infrared (FTIR) spectra were collected at room
temperature (25 °C). Data were collected over 256 composite scans with a resolution of 4
cm-1. The samples were analyzed in 20 mM acetate buffer at a con- centration of 3 mg/mL.
Spectra from buffer alone were subtracted from reactant and product spectra using the
OPUS spectroscopy software and data were further analyzed using GRAMS/AI (Galactic,
Inc.).
Nuclear Magnetic Resonance Spectroscopy
For structural analysis of the various reactants and conjugates, samples were dissolved in
D2O to a concentration of 10 mg/mL. H1 and C13 spectra were acquired on a Bruker 400
MHz spectrometer at 25 °C.
Gel Permeation Chromatography
The change in molecular weight of HA graft polymer conjugates was determined using a
Viscotek GPC max VE 2001 GPC solvent/sample module, VE3580 refractive index
detector, and 270 Dual Detector with right angle light scattering. Samples were separated by
utilizing a tandem column setup of an Agilent PL aquagel-OH 60 and Agilent PL aquagel-
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OH 40 column in seris. Columns were heated to 45°C using an Eldex CH-150 heating box.
All pullulan standards and graft polymer conjugates were separated in a 0.1 M Ammonium
Acetate, pH 5.0, with 0.25 M NaCl Mobile phase for 30 min.
High Performance Liquid Chromatography
Peptide was quantified by gradient reversed- phase HPLC (SHIMADZU) using a Vydac
HPLC protein and peptide C18 column. The HPLC consisted of a SCL-20A SHIMADZU
system controller, LC-10AT VP SHIMADZU liquid chromatograph, SIL-10A XL
SHIMADZU auto-injector set at 75 μL injection volume, DGU-14A SHIMADZU degasser,
sample cooler, and SPD-10A SHIMADZU UV-vis detector (220 nm). The HPLC-UV
system was controlled by a personal computer equipped with SHIMADZU class VP
Software. Gradient elution was carried out at constant flow of 1 mL/min, from 100% A to
35% A (corresponding to 0% B to 65% B) for 50 min, followed by an isocratic elution at
75% B for 3 min. Mobile phase compositions were (A) acetonitrile-water (5:95) with 0.1%
TFA and(B) acetonitrile-water 90:10, v/v) with 0.1% TFA. At the end of each analysis, the
cartridge was equilibrated at initial conditions at 1 mL/min flow rate for 5 min with A.
Induction of EAE and Therapeutic Study
SJL/J (H-2s) female mice, 4 – 6 weeks old, were purchased from Charles River Laboratory
and housed under specified, pathogen-free conditions at The University of Kansas. All
protocols involving live mice were approved by the Institutional Animal Care and Use
Committee. Mice were immunized subcutaneously with 200 mg of PLP139–151 in a 0.2 mL
emulsion composed of equal volumes of phosphate-buffered saline (PBS) and complete
Freund's adjuvant (CFA) containing killed Mycobacterium tuberculosis strain H37RA (final
concentration of 4 mg/mL; Difco). The PLP139–151/CFA was administered to regions
above the shoulders and the flanks (total of four sites; 50 μL at each injection site). In
addition, 200 ng/100 μL of pertussis toxin (List Biological Laboratories Inc.) was injected
intraperitoneally on the day of immunization (day 0) and 2 days post-immunization. The
mice received s.c. injections of each sample, equivalent to 100 nMol PLP /100 μL, on days
4, 7, and 10. For all samples and controls, 100 μL of each was injected. Disease progression
was evaluated blindly by the same observer using clinical scoring as follows: 0, no clinical
signs of the disease; 1, tail weakness or limp tail; 2, paraparesis (weakness or incomplete
paralysis of one or two hind limbs); 3, paraplegia (complete paralysis of two hind limbs); 4,
paraplegia with forelimb weakness or paralysis; and 5, moribund (mice were euthanized if
they were found to be moribund). Body weight was also measured daily.
Statistical Analysis
Statistical differences were determined by comparing treated groups to the negative control
(PBS) for clinical disease score and body weight. A one-way analysis of variance (ANOVA)
followed by Fisher's least significant difference was applied to these data. All analyses were
performed using GraphPad Software (GraphPad Software Inc.).
RESULTS
Intial studies focused on confirming reactivity of aminooxy-containing molecules and the
glycosaminoglycan hyaluronic acid (HA). The small molecules used were O-carboxymethyl
hydroxylamine (OCMH), O-benzyl hydroxylamine (OBZ), and O-phenyl hydroxylamine
(OPH). The structures of these molecules and the HA monomer unit are shown in Table 1.
Fourier Transform Infrared Spectroscopy (FT-IR) was used as a preliminary technique to
investigate reactivity between these aminooxy compounds and HA. Data showed distinct
changes in the FT-IR bonding environments when reacting either OCMH or OBZ (Figure
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1). In both product spectra, a new bonding environment appeared at 1750 cm-1 as well as a
distortion of the amide I peak at 1600 cm-1. The peak at 1750 cm -1 is representative of
formation of an oxime bond in the product. Additionally, the peak at 1500 cm-1 disappeared
and the peak environment around 1400 cm-1 was altered in both products, which may
suggest a change in the carboxylic acid environment of the HA.
Analysis of products by 1H NMR showed the appearance of new peaks in the product
spectra. The proton spectra for the OCMH conjugate (Figure 2B) and OBZ conjugate
(Figure 2C) showed three new peaks at 5.3 ppm, ~6.9 and 7.5 ppm, and 8 ppm when
compared to the HA polymer alone. In the OBZ spectra, there was an additional peak
environment at 7.3 ppm, however, this was due to the presence of the aromatic ring and not
associated with oxime bond formation. The environment at 5.3 ppm is indicative of the
hydrogens alpha to the aminooxy O-NH2. The doublet environments at ~6.9 and 7.5 ppm are
suggestive of the cis- and trans-conformation of the amide methyl group after addition.
Lastly, the environment at 8 ppm suggests addition at the carboxylic acid. Peak shifts are
supported by previous studies of oxime addition to polymers. [24, 25, 36, 37] These new
peak environments were also not present in the OCMH and OBZ control spectra
(Supplemental Figure 2).
In addition, 13C NMR further supported the observations seen in the 1H NMR. A new peak
appeared that was commensurate with an oxime bonding environment (~150 ppm). Also,
changes occurred in the carbonyl carbon environments, especially that of the carboxylic acid
at ~174 ppm, and ring environments at ~75 ppm corresponding to the grafted side chains
(Supplemental Figure 3). Although the data suggested the aminooxy reacted primarily at the
carboxylic acid site, the complex spectra for hyaluronan preclude a definitive assignment of
the reaction site (Supplemental Figure 4).
Two peptides with aminooxy N-termini were synthesized to further explore this conjugation
strategy. During solid phase synthesis, OCMH was simply reacted as the final coupling step
to introduce the aminooxy terminus. The peptides synthesized were aminooxy-proteolipid
peptide (PLP, aminooxy–HSLGKWLGHPDKF), a multiple sclerosis antigen and aminooxy-
LABL (LABL, aminooxy-ITDGEATDSG), a cell-adhesion peptide derived from leukocyte
function associated-antigen-1 (LFA-1). The peptides were then reacted with HA following
the same procedure as with the small molecule probes. Polymers with grafted LABL, or
with grafted PLP, were synthesized as well as polymers with both peptide species grafted.
Gel permeation chromatography was used to monitor the increase in apparent molecular
weight (MW) of the peptide-HA conjugate products versus the starting HA (Figure 3A). The
starting HA and graft polymer products were compared to pullulan standards to calculate
final MWs (Figure 3B). An increase in MW was observed that corresponded to the expected
products. Grafted PLP showed the greatest shift since PLP (MW= 1594) is larger than
LABL (MW=1032). The 1:1 ratio of grafted PLP:LABL appeared midway between the
other graft products as expected. Additionally, the theoretical number of peptides per HA
polymer was calculated using the estimated molecular weights (Table 2).
The graft polymers were furthered analyzed to determine the concentration of peptide that
was conjugated to the HA polymer. Oxime bonds are known to be labile to hydrolysis in
extremely acidic (≤ pH 2) or extremely basic solutions (≥ pH 9). The graft polymer
conjugates were incubated in three different pH solutions and the amount of released peptide
was determined using HPLC (Figure 4). At pH 2.0, the peptide was released from HA
rapidly and was fully released in ~100 min. At pH values closer to neutral, peptide was
released much slower.
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A mass balance was calculated for the graft polymer conjugates and released peptide based
on total reaction times of 8 hrs or 16 hrs (Table 3). A sixteen hour reaction time was
sufficient to obtain a conjugation efficiency >90%.
The final ratio of LABL:PLP peptide on the graft polymer conjugate was calculated based
on the amount of released peptide. Peptides were grafted close to the targeted 1:1 ratio
(Table 4) suggesting similar reactivity of the two aminooxy-peptides.
An animal study was conducted to investigate how the multivalent presentation of a disease-
specific antigen (PLP) alongside a co-grafted cell-adhesion inhibitor (LABL) would affect
disease progression. HA with grafted LABL and PLP peptides (~1:1 ratio) was injected
subcutaneously in the EAE model and significantly suppressed disease when compared to
the PBS negative control on days 11-15 (p<0.01). The graft polymer conjugates were also
compared to a dose of HA equivalent to the concentration of HA dosed with the graft
polymer conjugate. Although HA is a known CD-44 antagonist and can induce an anti-
inflammatory affect, HA did not suppress EAE when compared to PBS while the graft
polymer significantly suppressed disease progression (day 11 - 14, p<0.05) (Figure 5A)[38,
39]. The graft polymer conjugates were also compared to a physical mixture of free LABL
and PLP peptides to test whether the therapeutic effect was simply due to the presence of
both peptide species. The graft polymer conjugate provided significantly lower animal
scores when compared to free peptides (days 12-18, p<0.05) (Figure 5B).
The clinical scoring results were further supported by corresponding changes in animal
weight during the course of disease and a decrease in the incidence of disease for treated
mice (Supplemental Figure 5).
As an additional control, HA grafted with both PLP and LABL was compared in vivo
against a physical mixture of the individual scaffold components: HA polymer (MW 16900),
LABL peptide, and PLP peptide. The peptides did not contain the aminooxy reactive group.
Instead, each peptide had an unreactive amine terminus. The HA grafted with PLP and
LABL again significantly suppressed EAE (p<0.05) when compared to both the mixture of
physical components (Day 12-20) and to PBS (Day 12-21), while the physical mixture
showed no statistical difference compared to the PBS injections (Figure 6).
The clinical scoring results were further supported by corresponding changes in animal
weight during the course of disease and a decrease in the incidence of disease for treated
mice (Supplemental Figure 6).
DISCUSSION
Oxime chemistry has emerged as a powetful tool in conjugation reactions. Using this
scheme, small molecules, Pluronics®, and peptides or proteins have been conjugated to
polymers[23, 25, 40-42]. Unfortunately, functionalization of both the reactive adduct and the
polymer is typically necessary to confer reactivity. These multistep approaches to
conjugation can require lengthy and cumbersome synthesis schemes that ultimately produce
low yields of the end product. Additionally, when trying to utilize polysaccharide polymers
such as hyaluronic acid, functionalization with a reactive aldehyde group can cause the
breakdown of the polymer chain leaving a product that is much smaller than desired[43].
Because of these drawbacks, research has relied heavily on other conjugation techniques
such as “click chemistry”, thiol functionalization, or amine coupling[11, 44]. These
approaches also have drawbacks relating to reaction conditions and purification schemes.
Techniques such as carboiimde chemistry rely on enhancing the reactivity of carboxylic
acids and of primary amines. The potential for side products is high if these groups are
present in other parts of the reactive species. Simple conjugation schemes that can provide
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high reactivity and selectivity, with increased product yield via simplified reaction
conditions will be desired as more complex polymer conjugates are designed.
Hyaluronic acid has been used in oxime chemistry schemes. Researchers have targeted
either the “ring open” aldehyde of the reducing end of hyaluronic acid, or modified aldehyde
side groups added to the polymer[29, 43]. Chemical modifications were introduced to
encourage the oxime reaction to proceed through the traditional route of aminooxy addition
to an aldehyde or ketone. Here, the reactivity of aminooxy molecules directly to unmodified
hyaluronic acid was explored. Hyaluronic acid contains two carbonyl functional groups on
each monomer unit, a carboxylic acid and a methyl amide, that may confer reactivity. For
example, Gajewiak et al. theorized reactivity through the carboxylic acid in the synthesis of
their adherent glycosaminoglycan adducts[23].
Initially, a series of experiments were designed to monitor changes in chemical bonds of the
polymer and reactive species. Data acquired from FTIR and NMR showed reactivity
between small molecules containing the aminooxy group (OCMH and OBZ) and
unmodified HA. This was evident from changes in the carboxylic acid and amide
environments, as well as the appearance of new bonding environments in the FTIR data and
the presence of new peaks in the NMR. The polysaccharide ring environments in both the
FTIR and NMR data were maintained, suggesting that the HA backbone remained
unchanged. The proton NMR data showed the appearance of three distinct environments, all
suggestive of oxime reactivity at the carbonyl carbon centers on the HA molecule. These
data run counter to conventional wisdom, which has suggested that any latent reactivity of
aminooxy molecules to hyaluronic acid would proceed through “ring opening” of the
polymer backbone structure to yield aldehydes[45-47].
After validating the reactivity of small molecule probes, aminoxy peptide species were
conjugated to unmodified HA with a high degree of efficiency. Previous research that
utilized conjugation techniques such as carboiimide chemistry showed conjugation
efficacies of small molecule or peptide species from 10-50%[48, 49]. Here, data
demonstrated that aminooxy chemistry can be used to modify polysaccharides such as HA
via a “one pot” reaction with conjugation efficiencies >90%. The approach reported here
could have a dramatic impact on the design of graft polymers, enhancing the ability to
synthesize multifunctional conjugates.
The synthesis of multivalent graft polymers is of great interest in the area of immune
modulation. Previous research by Dintzis and others have shown that antigen display (i.e.
valency, number, density) and polymer characteristics (i.e. molecular weight, solubility) can
have dramatic effects on the immune response both in vitro and in vivo[2, 14, 50-52]. In this
historical work, immune response was markedly changed by subtle differences in the
physicochemical properties of polymers with grafted antigen. More recently, studies
investigating priming of T-cells for tumor immunotherapy demonstrated that the co-
localization of multiple cell signals could provide an enhanced and directed immune
response[53].
Siahaan and others previously demonstrated that the antigenic peptide PLP covalently linked
to the cell-adhesion inhibitor LABL suppressed the autoimmune disease EAE [54-57]. By
modifying the N-terminus of peptides with an aminooxy group, a multivalent graft polymer
conjugate displaying both this antigen for multiple sclerosis (PLP) and the cell-adhesion
inhibitor LABL was synthesized. HA with both grafted PLP and LABL was tested in vivo in
the EAE mouse model, which showed the characteristic peak in clinical scores followed by
partial remission of clinical symptoms. The graft polymers significantly suppressed EAE
compared to PBS and to HA treatment controls. The graft polymer conjugates also showed
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significant disease suppression compared to a mixture of the free peptides as well as a
mixture of all components: HA, PLP, and LABL. All control studies were conducted at
similar HA or peptide concentration as the HA with grafted PLP and LABL. Thus, both
peptide signals must be coincidently displayed along the polymer backbone to provide
therapeutic efficacy, a finding supported by reports from Siahaan and others denoting EAE
suppression when directly linking PLP and LABL peptides together [54, 56].
CONCLUSION
A simple approach for grafting aminooxy compounds to HA was proven using chemical and
biological studies. Small molecules or peptides containing aminooxy groups were
conjugated to hyaluronic acid in a single step under slightly acidic aqueous conditions.
Additionally, this oxime chemistry facilitated conjugation of two different peptides (PLP
antigen and LABL) to hyaluronic acid in an equimolar ratio. Graft polymers displaying both
of these peptides significantly suppressed disease in the EAE mouse model of multiple
sclerosis. The “one-pot” reaction scheme presented in this paper offers a simple approach to
the synthesis of graft polymers, colloids, or materials that display multiple copies of one or
more functional groups. Such an approach may enable new strategies for antigen-specific
immune modulation.
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The FTIR spectra of graft polymer products showed new peaks at ~1750 and ~1250 cm-1
and loss of the peak at ~1500 cm-1 when compared to the HA spectra (Supplemental Figure
1).
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1H NMR spectra for (A) HA, and for graft polymer products with (B) OCMH or (C) OBZ.
The OCMH and OBZ spectra show the appearance of new peaks suggesting oxime bond
formation at a -5.3 ppm, b - ~6.9 and 7.5 ppm, and c - 8 ppm. All data was compared to HA
and the individual monomer controls (Supplemental Figure 2).
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(A) SEC analysis of HA grafted with a single peptide (PLP or LABL) or grafted with a 1:1
peptide mixture showed an increase in MW as compared to unmodified HA. (B) Calibration
curve for pullulan standards used to calculate HA polymer graft conjugate product MW.
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The release of LABL peptide from HA was determined in three buffer conditions. Peptide
was released rapidly at pH 2.
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Graft polymer conjugates were evaluated in the EAE model. (A) HA grafted with PLP and
LABL significantly suppressed disease (p<0.05) when compared to both HA polymer (Day
11-14) alone and PBS controls (Day 11-15). (B) A physical mixture of free PLP and LABL
peptides showed no effect when compared to PBS control. Conversely, HA grafted with
PLP and LABL did significantly suppress disease (Day 12-18).
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HA grafted with PLP and LABL was compared to a physical mixture of HA, PLP peptide,
and LABL peptide. HA grafted with PLP and LABL significantly suppressed disease
(p<0.05) when compared to both the physical mixture (Days 12-20) and to PBS controls
(Days 12-21). The physical mixture of all components showed no effect when compared to
PBS control.
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Table 1
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Table 2
Calculated MWs for graft polymer conjugate products based on SEC.
Sample Calculated MW
* Theoretical Peptides per HA polymer
HA with grafted LABL 32145 31
HA with grafted PLP 60646 38
HA with grafted LABL and PLP 49080 37
*
Molecular weight estimated from pullulan standards
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Table 3
Mass balance of grafted HA (31 kDa) and unreacted aminooxy-LABL for the reaction times indicated.
Sample Area Under Curve Total Area of Peaks Reaction Efficiency Theoretical LABL per HA polymer
Aminooxy-LABL Peptide 8799141 8799141 n/a n/a
Grafted peptide (8 hr)
* 5633361
8774823 ~64% 26
Unreacted peptide (8 hr)
** 3141462
Grafted peptide (16 hr)
* 8421520
8421520 ~96% 41
Unreacted peptide (16 hr)
** Not detected
*
Peptide was first hydrolyzed from HA at pH 2
**
Total unreacted peptide in dialysate washes
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Table 4
HPLC analysis of peptides released from the HA (31 kDa) graft polymer.
Peptide Concentration (nMol) Mol% Theoretical # Peptide per HA polymer
Aminooxy-LABL Peptide 650 54 22
Aminooxy-PLP Peptide 550 46 19
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